Insurance coverage for GLP-1 medications like semaglutide and tirzepatide has always been a moving target, but many long-time users are discovering that coverage can change even after a year or more of smooth refills. A sudden prior authorization denial, a formulary switch, or a forced change from one GLP-1 to another can be disruptive — both financially and physically, since these medications are typically dosed on a gradual titration schedule.
Here’s some general context on why this happens and what may help if you’re navigating a coverage change.
Why coverage changes even when nothing about your prescription did
Formularies are reviewed and updated by insurers on a regular basis, sometimes annually, sometimes more often. A medication that was covered last year — or last quarter — can be moved to a higher tier, dropped from the formulary entirely, or made subject to new step-therapy requirements with little advance notice to patients. This isn’t unique to GLP-1s, but because these medications are in high demand and relatively expensive, they’ve become a frequent target for formulary revisions.
Why switching between GLP-1 medications isn’t a like-for-like swap
If a formulary change forces a switch — for example, from tirzepatide (Mounjaro/Zepbound) to semaglutide (Ozempic/Wegovy) — it’s important to understand these are different molecules with different dosing scales and mechanisms. According to the National Library of Medicine and clinical prescribing information, tirzepatide acts on both GIP and GLP-1 receptors, while semaglutide acts on GLP-1 receptors alone, and the two are not dosed on an equivalent milligram basis. This means restarting titration at a “base level” dose of a new medication — even after being on a high dose of a different one — is a deliberate safety measure, not an error, and some temporary change in appetite control or side effects during that adjustment period is expected.
The Mayo Clinic and other major health systems note that GLP-1 medications are generally titrated slowly specifically to reduce gastrointestinal side effects, and that switching therapies typically means going through a comparable adjustment period again.
What may help if you’re facing a coverage disruption
- Talk to your prescriber before making any changes. Only your prescribing clinician can advise on how to safely transition between GLP-1 medications, and whether a different titration pace or bridge plan makes sense for you — never adjust your own dose or switch medications without their guidance.
- Ask your pharmacy or prescriber’s office to file a formal appeal if a medication that was previously covered is suddenly denied; documentation of prior tolerance and response can sometimes support reinstatement.
- Look into manufacturer savings cards or patient assistance programs, which some GLP-1 manufacturers offer directly on their websites for eligible patients.
- Expect some fluctuation during a forced switch, and keep your care team looped in about weight changes, appetite, or side effects so they can adjust your plan as needed.
This article is for general educational purposes only and does not constitute medical advice. GLP-1 medications should only be started, stopped, or adjusted under the guidance of your prescribing healthcare provider — do not change your dose or switch medications on your own.
— Gemifys
